Evidence map›Paper›PMID 41249389›Full record

ArticleNPJ digital medicine2025

Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients.

Xichun Qin, Bo Cheng, Shangshang Ma, Kun Li, Yongfei Fan, Mingjun Li, Rangrang Wang, Xuefeng Ai, Leilei Wu, Xiucheng Liu and 2 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xichun Qin *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Bo Cheng *Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Shanghai, 200292, China.
Shangshang Ma *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Kun Li *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Yongfei FanDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Mingjun LiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Rangrang WangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Xuefeng AiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Leilei WuDepartment of Thoracic Surgery, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, 310005, China. wull@zjcc.org.cn.
Xiucheng LiuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. lxch2020@163.com.
Xiaojin WuDepartment of Radiation Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Jiefang South Road, No. 199, Xuzhou, 221000, China. wuxiaojinxz@126.com.
Dong XieDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. xiedong@tongji.edu.cn.

Funding

National Natural Science Foundation of China 82200999
6 · The paper itself

Abstract

Emotional distress (ED), including anxiety and depression, is highly prevalent in patients with non-small cell lung cancer (NSCLC) and may compromise both quality of life and treatment outcomes. In this study, we evaluated the mental health status of 1185 surgically treated NSCLC patients and developed a predictive model integrating clinical and demographic factors. Adjuvant therapy after lung cancer surgery was associated with an increased risk of ED, particularly chemotherapy. To address safety concerns, we further examined commonly used anti-ED drugs in experimental models and found no evidence of tumor-promoting effects. Importantly, tandospirone not only alleviates ED but also enhances the therapeutic efficacy of cisplatin. These findings highlight the clinical importance of systematic ED management in lung cancer care and suggest tandospirone as a promising candidate that may simultaneously support psychological well-being and improve chemotherapy response, offering a more comprehensive treatment strategy for NSCLC patients.

Identifiers

PMID41249389
PMCPMC12624032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.